October 25, 2023
Alkermes plc Reports Third Quarter 2023 Financial Results
October 23, 2023
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
October 18, 2023
Alkermes to Report Third Quarter Financial Results on October 25, 2023
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
Now in its seventh year, we are proud of the impact the Alkermes Inspiration Grants® program has made in support of creative and innovative programs designed to make a difference for patient communities. Visit the program page to learn about the latest group of grant recipients.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer
Nemvaleukin alfa - Mucosal Melanoma